Menstrual Migraine Prevention using Ubrelvy
This study will evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension
Inclusion Criteria:
- In order to be eligible for this study, you must be at least 18 years old and have a diagnosis of Menstrual Migraine
What to Expect
If patients are eligible after the 16 week screening period, they will enter the study and receive treatment to start taking 3 days prior to estimated start of menses and continue taking the treatment for 7 consecutive days
For more information please contact Andrea Bryan 716-250-2017, abryan@dentinstitute.com